This biomarker is also known as:
- Serine protease TADG-14,
- Tumor-associated differentially expressed gene 14 protein,
- kallikrein 8 (neuropsin/ovasin),
- kallikrein-related peptidase 8,
- Serine protease 19,
View in BioMuta
KLK8, a member of the kallikrein subgroup of serine proteases, is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. Kallikreins have been implicated in carcinogenesis, and some have potential as novel cancer and other disease biomarkers. KLK8 is one of fifteen kallikrein subfamily members located in a cluster on chromosome 19. The four isoforms of KLK8 are a result of alternate splicing of the gene. The isoforms exhibit distinct patterns of expression that suggest roles in brain plasticity and ovarian cancer.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
KLK8 alone was not shown to be a strong predictor of ovarian cancer.
Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.